טוען...
High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma
BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4(+) lymphocytes and their prognostic impact in lung cancer. We hypot...
שמור ב:
| הוצא לאור ב: | J Thorac Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6129889/ https://ncbi.nlm.nih.gov/pubmed/30233846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.45 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|